Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Tenet Health (THC)

Tenet Q4 net income rises to $371 million; adjusted EPS up 36.6% to $4.70

Positive Impact 4 of 5 earnings Written later

Tenet Healthcare reported fourth-quarter 2025 net income available to common shareholders of $371 million, or $4.22 per diluted share, up from $318 million, or $3.32, a year earlier. It also gave a full-year 2026 outlook, with Adjusted EBITDA expected between $4.485 billion and $4.785 billion, and disclosed a CommonSpirit agreement involving $1.9 billion in payments tied to Conifer Health Solutions.

Key points

  • Q4 2025 net operating revenues were $5.527 billion, up 8.9% from $5.073 billion in Q4 2024.
  • Q4 2025 adjusted diluted EPS rose 36.6% to $4.70 from $3.44; Adjusted EBITDA rose 12.9% to $1.183 billion.
  • Full-year 2025 net income available to common shareholders was $1.407 billion, or $15.49 per diluted share, versus $3.2 billion in 2024, which included a $2.916 billion pre-tax gain on hospital divestitures.
  • FY 2026 outlook: net operating revenues of $21.5 billion to $22.3 billion and Adjusted EBITDA of $4.485 billion to $4.785 billion.

The filing

CompanyTenet Health (THC)
Form8-K, current report
Filed with the SECFeb 11, 2026, 6:47 AM ET
Accession number0000070318-26-000007

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.